Drug name - Tlando

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8778922 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(6 years from now)

US11304960 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(6 years from now)

US8865695 ANTARES PHARMA INC Steroidal compositions
Jan, 2029

(6 years from now)

US9949985 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US11311555 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US11433083 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US10226473 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US9943527 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US11364249 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

US10716794 ANTARES PHARMA INC High-strength testosterone undecanoate compositions
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Product (NP) Mar 28, 2025

Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient

Market Authorisation Date: 28 March, 2022

Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
112.5MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.